Talphera (TLPH) Net Equity Issued and Repurchased (2011 - 2023)
Talphera (TLPH) posted Net Equity Issued and Repurchased of -$8.9 million for Q4 2023, down 4562.0% on a QoQ basis from $200000.0 in Q3 2022.
Analysis
Talphera (TLPH) Net Equity Issued and Repurchased (2011 - 2023) Analysis & Trends
Talphera has reported Net Equity Issued and Repurchased for 9 years, with the latest figure at -$8.9 million in Q4 2023.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$8.9 million in Q4 2023; TTM through Dec 2024 was -$8.7 million, a 0.0% change from a year earlier, with the FY2022 full-year figure at $239000.0, changed N/A from the prior year.
- Net Equity Issued and Repurchased was -$8.9 million for Q4 2023 at Talphera, down from $200000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $36.4 million in Q1 2021, with the low at -$36.4 million in Q4 2021.
- Average Net Equity Issued and Repurchased over 5 years is $2.1 million, with a median of $1.0 million recorded in 2019.
- The largest YoY upside for Net Equity Issued and Repurchased was 4537.76% in 2021 against a maximum downside of 465.91% in 2021.
- Over 5 years, Net Equity Issued and Repurchased stood at $1.2 million in 2019, then surged by 705.92% to $9.9 million in 2020, then sank by 465.91% to -$36.4 million in 2021, then jumped by 100.55% to $200000.0 in 2022, then plunged by 4562.0% to -$8.9 million in 2023.
- The last three Net Equity Issued and Repurchased figures came in at -$8.9 million (Q4 2023), $200000.0 (Q3 2022), and -$36.4 million (Q4 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 9.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 49.20 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -8.92 Mn |
| Sep 30, 2022 | 200,000.00 |
| Dec 31, 2021 | -36.36 Mn |
| Jun 30, 2021 | 7.50 Mn |
| Mar 31, 2021 | 36.36 Mn |
| Dec 31, 2020 | 9.94 Mn |
| Sep 30, 2020 | 9.95 Mn |
| Jun 30, 2020 | 665,000.00 |
| Mar 31, 2020 | 784,000.00 |
| Sep 30, 2019 | 1.23 Mn |
| Dec 31, 2018 | 52.45 Mn |
| Sep 30, 2018 | 21.67 Mn |
| Sep 30, 2013 | 1.25 Mn |
| Mar 31, 2013 | 84,000.00 |
| Sep 30, 2012 | 55,000.00 |
| Jun 30, 2012 | 19,000.00 |
| Mar 31, 2012 | 89,000.00 |
| Dec 31, 2011 | -3,000.00 |
| Sep 30, 2011 | 146,000.00 |